AOD-9604 Research Guide
AOD-9604 complete guide: mechanism, dosing schedules, fasting-window rules and expected results.
The fat-loss fragment of HGH
AOD-9604 is the C-terminal fragment (176-191) of human growth hormone. It retains the lipolytic portion of the molecule without the parts responsible for IGF-1 elevation or glucose effects, which is the reason it appears in fat-loss protocols instead of full HGH.
Dosing and timing
Research doses are 250–500 mcg subcutaneously once daily, usually fasted in the morning or before cardio. Because it does not raise GH or IGF-1, timing around meals matters less than with GHRPs but a fasted state is still the convention.
Realistic expectations
Human trial results for weight loss have been modest. AOD-9604 is best framed as an adjunct to a calorie deficit rather than a driver of it, and it is often stacked with a GLP-1 or a GH secretagogue rather than run alone.
Cycle length
Twelve weeks is a common block. It does not desensitise the pituitary, so cycle breaks are driven by cost and goal rather than by receptor concerns.
Frequently asked questions
Does AOD-9604 raise IGF-1?
No. The fragment lacks the growth-promoting regions of HGH, so IGF-1 and glucose effects are not expected.
What is the usual AOD-9604 dose?
250–500 mcg subcutaneously once daily, most often fasted in the morning.
Can AOD-9604 be stacked with a GLP-1?
Yes, they act by different mechanisms; the GLP-1 handles appetite while AOD-9604 targets lipolysis.